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A B S T R A C T   
Background: The effect of comorbidities on the prognosis of myasthenia gravis (MG) remains unclear. In 
particular, the role of other autoimmune diseases (AD) is controversial. 
Methods: In this retrospective single-center cohort study, we investigated 154 consecutive generalized thymec-
tomized MG patients, with a mean follow-up time of 8.6 (±5.0) years post-thymectomy. Comorbidities diagnosed 
at any timepoint were retrieved from medical records and Charlson comorbidity index (CCI) scores were 
calculated. Patients were categorized into subgroups MG alone (n = 45) and MG with any comorbidity (n = 109); 
the latter was further categorized into MG with other ADs (n = 33) and MG with non-AD comorbidities (n = 76). 
The endpoints analyzed were complete stable remission (CSR), minimal need for medications, and need for in- 
hospital treatments. 
Results: CSR was more frequent in MG alone than in MG with any comorbidity group (26.7% vs 8.3%, p = 0.004). 
Minimal need for medication was reached more often in the MG alone than in the MG with non-AD comorbidities 
group (p = 0.047). Need for in-hospital treatments was lower in the MG alone group than in MG patients with 
any comorbidity (p = 0.046). Logistic regression analysis revealed that lower CCI scores increased the likelihood 
of CSR (p = 0.033). Lower CCI scores were more prevalent both in patients with minimal need for medication and 
in patients who did not need in-hospital treatments (p < 0.001). 
Conclusions: Patients with generalized MG and comorbidities have a poorer prognosis than patients with MG 
alone during almost 9 years follow-up after thymectomy. AD comorbidities appeared not to translate into a 
higher risk compared to other comorbidities.   
1. Introduction 
Myasthenia gravis (MG) is an autoimmune disease of the neuro-
muscular junction, where exercise-induced and reversible loss of muscle 
strength are the key clinical features. However, the disease is diverse 
regarding the range of muscles involved, age at onset, pathological au-
toantibodies detected, eventual pathological findings of the thymus, and 
prognosis [1]. Antibodies against the acetylcholine receptor (AChR) are 
present in 85% of patients with generalized MG, whereas muscle- 
specific kinase (MuSK) is the target for antibodies in 5% of patients. 
Rare targets, such as low-density lipoprotein receptor-related protein 4 
(LRP4), have also been identified [2]. In early-onset generalized MG, 
symptoms start before the age of 50, patients are usually women, and 
thymic hyperplasia is found in 70% of patients, correlating strongly to 
AChR autoantibody production [3]. Late-onset generalized MG also 
presents with AChR autoantibodies, but both genders are equally 
affected and thymic hyperplasia is rare [1]. Thymoma as the inducer of 
MG has a paraneoplastic nature and explains 10% to 15% of all MG cases 
[4]. 
Treatment of MG may include cholinesterase inhibitors, non-specific 
immunosuppression, and thymectomy in patients <70 years with AChR 
autoantibodies or a thymoma [5]. In many observational studies, thy-
mectomy is associated with a reduction of immunosuppressive medi-
cation, decrease in symptoms and greater chance of complete stable 
remission (CSR) of also nonthymomatous MG [6,7]. In the only ran-
domized controlled trial performed to date, fewer thymectomized non-
thymomatous MG patients required prednisone-sparing 
immunosuppressants (17% vs 48%) or hospitalization for an 
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exacerbation of MG (9% vs 37%) than patients in the prednisone-only 
group 3 years after the operation, thus showing a sustained benefit [8]. 
The prognosis of MG is considered to be generally good and chronic 
symptoms can be managed with the treatments mentioned above [5]. 
However, CSR occurs in only 22% of AChR-positive MG patients [9]. 
Also, MG is classified as refractory in 10% to 20% of patients who do not 
achieve adequate response, do not tolerate available therapies, or 
require recurring in-hospital rescue therapies such as intravenous 
immunoglobulin (IVIG) or plasmapheresis (PLEX) [10]. Younger age at 
onset, female sex, history of thymoma, and positive MuSK antibodies are 
features associated with refractory MG [11,12]. 
Other autoimmune diseases (ADs) are strongly associated with MG. 
MG patients have a 22% risk of another AD during their lifetime, 
compared to 9% in an age- and sex-matched control group randomly 
selected from the MG-free general Swedish population [13]. Thyroiditis, 
systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, 
Addison's disease, dermato- or polymyositis, and neuromyelitis optica 
are the ADs most commonly associated with MG [13–17]. Co-occurrence 
of another AD is more common with early-onset than late-onset MG 
[17]. Thyroiditis also often co-occurs with the ocular, usually mild form 
of MG [14,18]. Thymoma-induced MG, on the other hand, is associated 
with hematological ADs and autoimmune myocarditis [1]. Interestingly, 
a recent Taiwanese study concluded that patients with or without MG 
who underwent thymectomy had a higher risk of new onset AD [19]. 
Currently, non-autoimmune comorbidities, such as type 2 diabetes, 
hypertension, and coronary diseases, are common in MG due to 
increased life expectancy and are understandably more common in pa-
tients with late-onset MG [20]. 
The effect of comorbidities on the prognosis of MG and treatment 
response is still unclear. One study reported that patients with autoim-
mune comorbidities were at considerable risk for a relapse of MG [21]. 
In another study, autoimmune thyroid disease did not seem to increase 
the risk of myasthenic crises or to reduce response to medication [18]. In 
a Mexican study, response to thymectomy did not differ between MG 
patients with or without other ADs [22]. One study on 88 MG patients 
reported that patients with more than two comorbidities, autoimmune 
or non-autoimmune, had a greater risk for a crisis of MG and a generally 
poorer outcome [20]. 
Considering the notable differences in disease severity and patho-
logical profiles in MG, we sought to control these variables by investi-
gating a series of consecutive generalized MG patients with thymectomy 
and with an extensive follow-up time to determine the effect of 
comorbidities on the prognosis of generalized MG. 
2. Materials and methods 
2.1. Data collection 
For this retrospective single-center cohort study, our series consisted 
of consecutive patients with generalized MG who had undergone a 
thymectomy between 1999 and 2015. The patient data have been 
characterized in detail by Kauppi et al. [23]. The patients were followed 
from diagnosis of MG to the last follow-up visit at the neurology 
outpatient clinic. Data for comorbidities diagnosed at any time point 
before or after thymectomy were collected from hospital patient medical 
records, and the number and nature of comorbidities before thymec-
tomy and of those emerging during the post-thymectomy follow-up were 
determined. Comorbidities were captured only if there was a diagnosis 
found in the chart, and possible subclinical undiagnosed comorbidities 
were not searched for. The latest review of the patients' data was per-
formed in April 2020. Neurologists diagnosed MG based on clinical 
presentation, anti-AChR and anti-MuSK antibody serology tests, and 
electrophysiological tests (ENMG). The severity of MG was graded using 
the Myasthenia Gravis Foundation of America Clinical Classification 
(MGFA) as I to V during review of patient records; MGFA class I means 
any ocular muscle weakness, class II mild generalized weakness, class III 
moderate generalized weakness, class IV severe generalized weakness, 
and class V intubation with or without mechanic ventilation [24]. 
Clinical parameters of the study were use of immunosuppressive 
drugs, pyridostigmine dose, discontinuation of all MG medication, need 
for admission to the intensive care unit (ICU), and need for high-dose 
intravenous methylprednisolone (IVMP), PLEX, or IVIG treatment. 
CSR was defined as discontinuation of all medication (including 
acetylcholinesterase inhibitors such as pyridostigmine) for MG at least 
12 months before the last follow-up visit and no evidence of active 
disease thereafter. Patients classified to have a minimal need of medi-
cation were those in CSR or using pyridostigmine as the only medication 
(maximum 100 mg per day). Need for in-hospital treatments for exac-
erbations of MG was treatment at ICU or receiving IVMP, PLEX, or IVIG 
treatment during the follow-up period after thymectomy until the last 
follow-up visit. Clinical predictors were compared between patients 
with or without comorbidities. We formed subgroups based on comor-
bidities. The first subgroups were MG patients without any comorbid-
ities (MG alone) and MG patients with any comorbidity. We then divided 
the latter subgroup further into patients with MG and other AD and MG 
patients with comorbidities other than AD (MG with non-AD comor-
bidity). Patients that had both other ADs and other comorbidities were 
assigned to the group MG with other AD. 
To further investigate the role of comorbidities in MG, we calculated 
a score for comorbidity by the Charlson comorbidity index (CCI). CCI is a 
summary measure that estimates risk of death from comorbid diseases 
and patient age and is widely used by researchers to measure burden of 
disease. The index considers 17 different comorbid conditions, such as 
cancer, diabetes, or congestive heart failure. The weight of each con-
dition is estimated by its severity. Of autoimmune diseases, type 1 dia-
betes, connective tissue diseases, and autoimmune diseases of the liver 
and kidney are included. Comorbid conditions are assigned a score from 
one to six points, and weighted scores are summed to provide a summary 
score or CCI. The higher the summary score, the higher the risk of 1-year 
mortality [25,26]. 
The study was approved by the institutional review board of Helsinki 
University Hospital. According to Finnish law, approval of the ethical 
committee was not required because the study was based on hospital 
medical records and included no contact with patients. 
2.2. Statistical methods 
Statistical analyses were performed with SPSS software version 25 
(IBM, New York). Demographic data were described by means and 
standard deviations (SD) for normally distributed variables and medians 
and ranges otherwise. We compared continuous variables by the Mann- 
Whitney U test and categorical variables by Fisher's exact test. We used 
logistic regression analysis for continuous variables. A p-value of <0.05 
was considered statistically significant. 
3. Results 
3.1. Demographics of the study population and prevalence of 
comorbidities 
Of the 154 patients studied, 76 (49.0%) were females. ENMG test was 
positive in 139 patients (90.3%), AChR antibodies were detected in 130 
patients (84.4%), and MuSK antibodies in 1 patient (0.7%). Thymoma 
was found in 7 patients (4.5%). The mean total follow-up time was 9.6 
(±5.3) years and the mean follow-up time from thymectomy to the last 
follow-up visit was 8.6 (±5.0) years. 
Demographic and clinical characteristics of the studied MG sub-
groups are presented in Table 1. Forty-five patients in the study popu-
lation had MG alone at the end of follow-up. From the total of 109 
patients with any comorbidity, 33 (21.4%) had other ADs and 76 
(49.4%) had non-AD comorbidities at the end of follow-up. We included 
all patients who had other ADs into the MG with other AD group, 
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although 23 of these patients also had a non-AD comorbidity. The sub-
group analysis showed that patients with MG alone were more often 
women, and mean age at time of MG diagnosis was clearly lower than in 
the other subgroups (34.4 [±16.8] years vs 54.8 [±14.3] years in pa-
tients with any comorbidity; P < 0.0001). MGFA class at time of diag-
nosis was not significantly different between groups. The follow-up time 
of the study was longer for patients with comorbidities (8.2 [±5.3] years 
for MG alone vs 10.2 [±4.9] years for MG with any comorbidities; p =
0.026). 
The prevalence of comorbidities in the study population is shown in 
Table 2a. During the post-thymectomy follow-up, there were a total of 
39 individual patients diagnosed with altogether 49 new comorbidities, 
of which 19 were cardiovascular or metabolic or most likely related to 
these two classes (i.e. sleep apnea, 5 patients). Two patients had MG 
alone before thymectomy and developed non-AD comorbidities before 
the end of follow-up. Eleven new diagnoses of an AD were made during 
the post-thymectomy follow-up, of which ten to patients who had no 
other diagnoses besides MG at the time of thymectomy. Autoimmune 
thyroid disease was the most common AD observed at the end of follow- 
up and accounted for 50% (n = 20) of AD cases. Almost half of all pa-
tients had two or more of any kind of comorbidities at the end of follow- 
up (n = 71, 46.1%). The median CCI score at the end of follow-up was 2 
and the highest score was 6 (n = 2) (Table 2b). The MG alone group had 
5 patients with CCI score of 2, which is due to the points assigned from 
age of patient. 
Patients with thymoma (n = 7) were slightly older at the time of 
diagnosis than non-thymomatous MG patients (n = 147, 57.4 [±16.8] 
years vs 48.3 [±17.0] years). Two of the patients were female, and mean 
follow-up time was 7.0 (±5.3) years. None of the thymomatous MG 
patients had other ADs before thymectomy, but one developed an other- 
Table 1 
Demographic parameters of the study subgroups*.   
MG 
alone 
MG with comorbidities** 




MG with non- 
AD 
comorbidity 
N (% of total group) 45 
(29.2%) 
109 (70.8%) 




p < 0.001 
Female, n (%) 34 
(75.6%) 
42 (49.4%) 






p < 0.0001 
Age at diagnosis of 











p < 0.0001 
Age at thymectomy, 















in years (±SD) 
0.7 
(±1.4) 





MGFA class at the 
time of diagnosis, n 
(%)     
I 10 
(22.2%) 










26 (23.9%) 9 
(27.3%) 
17 (22.4%) 
IV 0 2 (1.8%) 1 (3.0%) 1 (1.3%) 
V 1 (2.2%) 2 (1.8%) 0 2 (2.6%) 
Total follow-up time, 













the last follow-up 











* Study subgroups were formed based on the presence of comorbidities at the 
end of follow-up. **Patients with both other AD comorbidity and non-AD co-
morbidity were included in the MG with other AD subgroup. MG myasthenia 
gravis; AD autoimmune disease; MGFA Myasthenia Gravis Foundation of 
America; p-values for statistically significant differences between MG alone and 
the other subgroups studied are shown; those not shown were insignificant. 
Table 2 




Number of patients before 
thymectomy (% of all 
patients, n = 154) 
Number of patients at the 
end of follow-up (% of all 
patients, n = 154) 
Cardiovascular 
disease 
56 (36.4%) 62 (40.3%) 
Metabolic disease 24 (15.6%) 30 (19.5%) 
Respiratory disease 18 (11.7%) 23 (14.9%) 
Cancer 9 (5.8%) 18 (11.7%) 
Mental disorder 9 (5.8%) 10 (6.5%) 
Other neurological 
disease 
4 (2.6%) 9 (5.8%) 
Other diseases 8 (5.2%) 8 (5.2%) 
Musculoskeletal 
disease 
1(0.6%) 3 (1.9%) 
Hematological 
disease 




17 (11.0%) 20 (13.0%) 
Rheumatoid arthritis 4 (2.6%) 6 (3.9%) 
Ulcerative colitis or 
Crohn's disease 
3 (1.9%) 4 (2.6%) 
Psoriasis 2 (1.3%) 4 (2.6%) 
Henoch-Schönlein 
purpura 
1 (0.6%) 2 (1.3%) 
Primary sclerosing 
cholangitis 
0 1 (0.6%) 
Systemic lupus 
erythematosus 
1 (0.6%) 1 (0.6%) 
Celiac disease 1 (0.6%) 1 (0.6%) 
Polymyalgia 
rheumatica 
0 1 (0.6%)  
Prevalence of non-autoimmune and autoimmune comorbidities, shown both 
before thymectomy (on the left) and at the end of follow-up (on the right). 
Cardiovascular diseases reported were hypertension, coronary artery disease, 
cardiac arrhythmia, congenital heart defect, and heart failure. Metabolic dis-
eases were type 2 diabetes, hypercholesterolemia, and gout. Respiratory dis-
eases were asthma, sleep apnea, chronic bronchitis, asbestosis, pulmonary 
sarcoidosis, chronic respiratory failure. Other neurological diseases were epi-
lepsy, Parkinson's disease, Alzheimer's disease, migraine, trigeminal neuralgia, 
and transient ischemic attack. Hypertension was the most prevalent single co-
morbidity (n = 58). MG myasthenia gravis. 




MG alone, n 
(%, out of 
45 patients) 
MG with any 
comorbidity, n 
(%, out of 109 
patients) 
MG with 
other AD, n 
(%, out of 33 
patients) 
MG with non-AD 
comorbidity, n (%, 
out of 76 patients) 
0–1 40 (88.9%) 26 (23.9%) 9 (27.3%) 17 (22.4%) 
2–4 5 (11.1%) 69 (63.3%) 20 (60.6%) 49 (64.5%) 
5–6 0 14 (12.8%) 4 (12.1%) 10 (13.2%) 
*The CCI scores were calculated based on the presence of comorbidities at the 
end of follow-up. CCI Charlson comorbidity index; MG myasthenia gravis; AD 
autoimmune disease. 
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AD during post-thymectomy follow-up. 
3.2. Treatment of MG and achievement of CSR in the studied subgroups 
The rate of in-hospital treatments for exacerbations of MG during the 
follow-up period after thymectomy is shown in Table 3. IVMP was given 
significantly more often to patients with any comorbidities when 
compared with MG alone (35.8% vs 17.8%; p = 0.034). Other ADs as 
comorbidities were unremarkable. There were no significant differences 
in postoperative ICU admission, PLEX, or IVIG treatment among any of 
the studied subgroups. 
Immunosuppressive drugs were used more frequently in the MG with 
any comorbidities group than in the MG alone group at the last follow- 
up visit (41.3% vs 20.0%; p = 0.015). Immunosuppressive drugs pre-
scribed included oral prednisolone (18 patients), azathioprine (36 pa-
tients) and methotrexate (4 patients). Again, other ADs as comorbidities 
were unremarkable. There was no difference in the mean pyridostig-
mine dose between any of the subgroups. 
CSR was significantly more frequent in MG patients without 
comorbidities as compared with MG patients with any comorbidity 
(26.7% vs 8.3%; p = 0.004). This difference remained when dividing the 
comorbidities into other ADs (26.7% vs 6.1%; p = 0.034) and non-AD 
comorbidities (26.7% vs 9.2%; p = 0.018). 
We further performed a binary logistic regression analysis to assess 
the impact of gender, age at MG diagnosis, and CCI score (independent 
variables) on the likelihood of achieving CSR. The regression model was 
statistically significant (χ2 (3) = 12.848; p < 0.005) and correctly clas-
sified 85.6% of cases. The model overall explained between 8.1% (Cox 
and Snell R square) and 14.4% (Nagelkerke R squared) of the variance in 
CSR. Only the CCI score made a statistically significant unique contri-
bution to the model, with lower CCI scores increasing the likelihood of 
reaching CSR (p = 0.033) (Table 4). Pearson correlation coefficient for 
age at MG diagnosis and CCI score at the end of follow-up was very 
strong (r = 0.837, p < 0.001). 
3.3. Minimal need for medication after thymectomy and need for in- 
hospital treatments for exacerbations of MG after thymectomy 
We next assessed minimal need for medication after thymectomy, 
defined as CSR or maximum dose of 100 mg per day of pyridostigmine 
alone. This endpoint was reached significantly more often in the MG 
alone group than in the MG with non-AD comorbidities group (p =
0.047) (Table 3). There were no significant differences between the 
other subgroups. We used the CCI score to further analyze the effect of 
comorbidities on this endpoint. The distributions of the CCI score be-
tween patients with minimal need for medication and patients with 
more medications were significantly different in the entire study pop-
ulation (Mann-Whitney U test; p < 0.001) (Fig. 1a). 
Need for in-hospital treatments for exacerbations of MG during the 
post-thymectomy follow-up was also analyzed. There was a significant 
difference between MG alone and MG with any comorbidity subgroups 
regarding this endpoint (p = 0.046) (Table 3). Dividing the comorbid-
ities into other ADs and non-AD comorbidities did not yield a significant 
difference compared to the MG alone group. The distributions of the CCI 
score between patients who required in-hospital treatments and patients 
managed with regular outpatient care in the entire study population 
were also significantly different (Mann-Whitney U test; p < 0.001) 
(Fig. 1b). 
Patients with thymomatous MG (n = 7) did not reach CSR, but the 
number of patients in need of in-hospital treatments was similar to non- 
thymomatous cases (57.1% vs 38.7%). 
4. Discussion 
This study shows that patients with generalized MG who have 
comorbidities are less likely to achieve CSR during the post-thymectomy 
follow-up than patients with MG alone, and that the effect is similar with 
both autoimmune and non-autoimmune comorbidities. We used CCI 
score to quantify the overall burden of comorbidities. CCI score in a 
logistic-regression model revealed a significant inverse correlation to 
achievement of CSR when known confounding factors of age at diag-
nosis and gender [11] were considered. The percentage of patients 
achieving CSR was significantly higher in the MG alone group. The 
prevalence of other ADs (21.3%) and the range of ADs present were 
consistent with previous reports [1,13,20,22], with a preponderance of 
autoimmune thyroid disease. Non-AD comorbidities were common, with 
the most common comorbidity of hypertension diagnosed in 37.7% of 
all patients in this study. Minimal need for medication at the end of 
follow-up was significantly more likely in the MG alone group than in 
patients with non-AD comorbidities and likewise for those with low CCI 
scores. Need of in-hospital treatments for exacerbations of MG was more 
common in patients with any comorbidity than in patients with MG 
alone and likewise for those with high CCI scores. 
Our results are consistent with a previous study that revealed an 
association between comorbidities with poorer prognosis regarding the 
Table 3 
Treatment of myasthenia gravis (MG) and achievement of complete stable 
remission (CSR) during the post-thymectomy follow-up in the subgroups.  
Patients given in- 
hospital treatments for 
an exacerbation, n (%) 
MG 
alone 














p = 0.024 
PLEX 2 (4.4%) 15 (13.8%) 5 
(15.1%) 
10 (13.2%) 
IVIG 2 (4.4%) 9 (8.3%) 5 
(15.1%) 
4 (5.3%) 
ICU 3 (6.7%) 15 (13.8%) 4 
(12.1%) 
11 (14.5%) 
Patients in need of in- 
hospital treatments 
during the post- 
thymectomy follow- 









drugs at the last 








p = 0.017 
Pyridostigmine dose at 
the last follow-up 










CSR at the last follow- 




p = 0.004 
2 (6.1%) 
p = 0.034 
7 (9.2%) 
p = 0.018 
Minimal need for 
medication at the last 




20 (18.3%) 7 
(21.2%) 
13 (17.1%) 
p = 0.047 
AD autoimmune disease; IVMP intravenous methylprednisolone; PLEX plasma-
pheresis; ICU intensive care unit; IVIG intravenous immunoglobulin. †CSR was 
defined as discontinuation of all MG medication at least 12 months before the 
last follow-up visit and no evidence of active disease thereafter. ‡ Minimal need 
for medication was defined as complete stable remission (CSR) or maximum 
dose of 100 mg per day of pyridostigmine alone. p-values for statistically sig-
nificant differences between MG alone and the other subgroups studied are 
shown; those not shown were insignificant. 
Table 4 
Logistic regression model for complete stable remission (CSR).   
OR 95% CI p-value 
Gender 1.44 0.46–4.51 0.533 
Age at diagnosis 1.00 0.95–1.06 0.785 
CCI score 0.51 0.28–0.95 0.033* 
OR odds ratio; CI confidence interval. *Statistically significant at the p < 0.05 
level. 
S.M. Laakso et al.                                                                                                                                                                                                                              
Journal of the Neurological Sciences 427 (2021) 117549
5
need for in-hospital treatments for MG [20]. Other comorbid ADs when 
compared with non-AD comorbidities were unremarkable in terms of 
prognosis. This observation is in contrast to Wang et al. 2017 but 
consistent with Kubiszeska et al. 2016 [18,21]. Our study addressed the 
issue of numerous clinical variables that affect the severity of MG by 
focusing on generalized MG that the clinician had assessed to be severe 
enough to warrant thymectomy. Generalisability of our results into 
patients not perceived to benefit from thymectomy is therefore ques-
tionable. Thymectomy as the starting point of the study population se-
lection might also explain differences to previous studies. However, a 
similar study approach and a comparative sample size was used by 
Téllez-Zenteno et al. 2004 [22] with contrasting results, which may be 
due to differences in patient selection. 
Our study had a substantial mean follow-up time of 8.6 years (±5.0) 
after thymectomy, which increases the likelihood of capturing all rele-
vant diagnoses even when using retrospective patient record review as 
the method of data collection. MG treatment is centralized at our hos-
pital. MG exacerbations requiring in-hospital treatment are directed in 
Finland to public hospitals that are all in the same electronic patient 
record system in our hospital district. Comorbidities can also be diag-
nosed and treated in the private sector but are still recorded in patient 
records, especially for MG patients, as all medications must be consid-
ered when assessing the causes of possible disease progression. All pa-
tients in the study population were under regular follow-up at the 
outpatient clinic, which increases the reliability of the data. We did not 
however search for subclinical undiagnosed autoimmune diseases, 
which is a limitation of the study. Studying a consecutive series of MG 
patients undergoing thymectomy further increases the relevance of our 
data in describing the patient population at hand. 
A limitation in our study approach is that patients with MG alone 
were significantly younger than patients with comorbidities. Younger 
age at thymectomy might be a confounding factor for better response to 
the operation, because thymic hyperplasia and subsequent higher pro-
duction of AChR antibodies is more prevalent in patients under the age 
of 50, and thymic involution with age correlates with lowering numbers 
of germinal centers in the thymus [3]. We sought to confirm the findings 
of subgroup analysis by using the CCI score for the entire study popu-
lation. However, this limitation remains as age is also a factor in the CCI 
score, and there was a significant correlation between age at MG onset 
and CCI score at the end of follow-up. Interestingly, younger age at 
disease onset in itself is associated with the risk of refractory MG 
[11,12]. Therefore, based on our results, it can be hypothesized that 
comorbidities could outweigh age at disease onset as a risk factor for 
refractory MG. 
Another point of concern is, whether immunosuppressive treatments 
for MG, especially corticosteroids, have contributed to the emergence of 
new non-AD comorbidities, and therefore form a confounding factor in 
the study. Our approach of classifying patients into subgroups MG alone 
and MG with comorbidities was however not substantially affected by 
this, because only two out of 76 patients entered the subgroup MG with 
non-AD comorbidities during the post-thymectomy follow-up. 
The method of retrospective data collection and moderate sample 
size (n = 154) are also limitations in this study. We wanted to study 
especially the effect of having other ADs in this setting, and therefore 
included 23 patients into the MG with other AD group that also had non- 
AD comorbidities. Non-AD comorbidities could therefore also affect the 
results of the MG with other AD group. The rationale for our choice was 
to achieve a reasonable size of the subgroup and to determine if having 
other ADs in itself would change the prognosis. Our results indicate that 
other ADs do not substantially change the prognosis of MG compared to 
the effect that non-AD comorbidities have, as these subgroups had 
similar results regardless of the clinical parameters used. It is however of 
interest that thymectomy did not seem to protect the MG patients from 
developing new ADs, nor lessen the effect of other AD comorbidities on 
the prognosis. Extra-thymic plasma cells are thought to contribute to 
persistent antibody generation after thymectomy, which is most likely of 
relevance here [27]. 
MGFA score at diagnosis was not significantly different in the sub-
groups. This highlights the differences in outcome measures emerging 
later in follow-up and with the short time interval between diagnosis 
and thymectomy, most likely in the post-thymectomy period. However, 
it should be noted that the follow-up time of patients both in total and 
after thymectomy was shorter for patients with MG alone, and this might 
affect our results. 
Further studies on the exact comorbidities affecting the prognosis of 
generalized MG are needed. Larger study samples would be beneficial. A 
nationwide study is warranted considering the increasing but still quite 
low prevalence of MG, recently estimated to be 29/100,000 in Finland 
based on data from drug reimbursement rights [28]. Whether in-
dications for thymectomy should be different for patients with comor-
bidities cannot be answered based on our study, and this should be 
addressed further. The impact of comorbidities on the prognosis of 
MuSK autoantibody-positive MG patients and those with thymoma, both 
groups associated with a higher risk of refractory MG [5], remain 
outside the scope of this study due to the low patient numbers and 
should be studied further. 
In conclusion, our study shows that patients with generalized MG 
and comorbidities have a poorer prognosis after thymectomy than pa-
tients with MG alone, and this effect prevails after almost 9 years of 
follow-up. AD comorbidities do not seem to be a higher risk compared to 
Fig. 1. a) Patients with minimal need for medication at the end of follow-up 
and patients that were prescribed more medications distributed by the Charl-
son comorbidity index (CCI) score (n = 154). Minimal need for medication was 
defined as complete stable remission (CSR) or maximum dose of 100 mg per 
day of pyridostigmine alone. The distributions of the CCI score were signifi-
cantly different (p < 0.001; Mann-Whitney U test). b) Patients that need in- 
hospital treatments in the post-thymectomy follow-up and patients managed 
with regular outpatient care distributed by the CCI score (n = 154). The dis-
tributions of the CCI score were significantly different (p < 0.001; Mann- 
Whitney U test). 
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other comorbidities. Thymectomy is a beneficial treatment for gener-
alized MG, but not sufficient to limit disease activity especially in pa-
tients with comorbidities. Clinical decision-making guidelines for the 
treatment of MG emphasize considering disease heterogeneity [29]; Our 
results indicate that comorbidities have a significant effect on the 
presence of symptoms of MG, and should be evaluated along with other 
factors known to affect the severity of MG. 
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